Dasatinib Early Intervention After Cytogenetic or Hematologic Resistance to Imatinib in Patients With Chronic Myeloid Leukemia

BACKGROUND: Although many patients with chronic myeloid leukemia (CML) respond well to imatinib therapy, a significant proportion loses their initial response. Loss of response on imatinib is often because of BCR-ABL mutations. Dasatinib is a 325-fold more potent inhibitor of Bcr-Abl than imatinib a...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Quintás-Cardama, Alfonso, Cortes, Jorge E., O'Brien, Susan, Ravandi, Farhad, Borthakur, Gautam, Liu, David, Bleickardt, Eric, Chen, Tai-Tsang, Kantarjian, Hagop M.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2009
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4176768/
https://ncbi.nlm.nih.gov/pubmed/19402171
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.24325
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares